New U.S. patent for neflamapimod in pure DLB patients propels CRVO
- CervoMed received USPTO notice of allowance for patent protecting neflamapimod use in DLB without substantial Alzheimer's tau pathology
- Patent provides IP exclusivity into 2042 (potentially longer with extensions), issued via GlobeNewswire on June 18
- Strengthens position for Phase 3 trial initiation in H2 2026 and strategic partnering; no approved DLB therapies exist in US/EU
- Builds on recent RewinD-LB Phase 2b data showing efficacy and FDA-aligned registration path announced in prior months
- Stock rebounded from ~16% decline on June 17; small-cap biotech volatility amplified retail and momentum interest
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.